^
    1d
    Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders. (PubMed, Pharmacol Res)
    Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib)...Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
    FDA event • Review • Journal
    |
    BTK (Bruton Tyrosine Kinase) • PLCG2 (Phospholipase C Gamma 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase)
    |
    Imbruvica (ibrutinib) • imatinib • cyclophosphamide • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • vincristine • prednisone • Jaypirca (pirtobrutinib) • Rhapsido (remibrutinib)
    6d
    CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy. (PubMed, J Clin Exp Hematop)
    Chemotherapy with rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) led to prompt improvement in serum albumin levels and resolution of the protein-losing enteropathy. Subsequent high-dose chemotherapy with autologous stem cell transplantation has maintained remission. Given the rarity of this presentation and its strong similarity to a previously reported case of CD5-positive DLBCL with protein-losing enteropathy, we propose that this might represent a distinct clinical entity.
    Journal
    |
    CD5 (CD5 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    11d
    High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes. (PubMed, Am J Hematol)
    In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2-expressing Tregs.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    13d
    CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=131, Not yet recruiting, Henan Cancer Hospital
    New trial • Real-world evidence
    13d
    MAZ-01: Zanubritnib and anti-MAG neuropathy (2025-523091-23-00)
    P1/2, N=50, Recruiting, Azienda Ospedaliera di Padova | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    14d
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (clinicaltrials.gov)
    P2, N=145, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
    17d
    ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2028 | Trial completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • evorpacept (ALX148)
    17d
    NX-2127-001: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=248, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    CD4 (CD4 Molecule)
    |
    zelebrudomide (NX-2127)
    19d
    Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process. (PubMed, Haematologica)
    In contrast, majority of BCL6 translocations in thyroid EMZL juxtaposed the BCL6 gene to the IGHJ/D region without encompassing the Eμ enhancer or its partner genes in an opposite orientation, thus less likely to lead to constitutive BCL6 transactivation. The above genetic changes likely dysregulate B-cell maturation and peripheral tolerance, thus offer significant molecular insights into the pathogenesis of thyroid lymphomas, particularly underpinning autoimmunity in the lymphomagenesis and potentially explaining the overlap in histopathology between EMZL and FL.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • TNFRSF14 (TNF Receptor Superfamily Member 14) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
    |
    TET2 mutation • EZH2 mutation
    20d
    CLOVER-WaM: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    iopofosine I-131 (CLR 131)
    20d
    Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)
    21d
    A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (clinicaltrials.gov)
    P1, N=84, Terminated, MEI Pharma, Inc. | Recruiting --> Terminated; Business reasons, not related to safety or efficacy results.
    Trial termination
    |
    Venclexta (venetoclax) • voruciclib (ME-522)